Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 13.75p 13.00p 14.50p 13.75p 13.75p 13.75p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.0 1.6 1.9 7.1 15.05

Synairgen Share Discussion Threads

Showing 976 to 999 of 1000 messages
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
DateSubjectAuthorDiscuss
06/12/2018
08:29
Thanks nobby Duly noted
timbo003
05/12/2018
11:53
ohisay - looks like a giant rollover. Pair of trades at over £500k. Appears that someone's got a punt of over half a million running on this and is maintaining their position.
richthenewbie
05/12/2018
11:32
>> timbo Very interesting data and yes, if it is a real effect, you would have to expect that this SNP would be relevant for any treatment with interferon. However, we are talking about very low numbers of patients here. As far as I can work out there is 5 deaths in the non SNP group and 2 in the SNP group. Although this result is apparently statistically significant this could be down to chance IMHO. After all the trial was not set up with this analysis in mind so you have to be very wary of such data. Happy to be proved wrong with my interpretation of the numbers above.... Nobby
nobbygnome
05/12/2018
10:06
Blimey 7m shares traded at 15p..
ohisay
05/12/2018
09:17
Yes interesting . Thats in addition to the other subgroup? that weren't taking corticosteroids (was it 40% in the last trial ?) .
ohisay
05/12/2018
08:06
Released this morning from Faron: https://www.investegate.co.uk/faron-pharma--oy--farn-/rns/patient-subgroup-identified-from-interest-trial/201812050700024471J/ Fascinating stuff, I wonder if there are any other real world consequences for the circa 40% of individuals with the mutation? I assume that those of us with the mutation are walking around blissfully unaware that we have it, or does the mutation manifest its self in other ways? Given that Interferon is also used to treat MS and COPD exacerbations (Synairgen), I cannot help wondering whether this relatively common mutation is going to have an influence in outcomes for those two indications when treated with interferon. Any thoughts?
timbo003
04/12/2018
11:48
Phillips has said in the last few weeks they are looking for an "ambitious" partner for Loxl2 so more likely than not thst the two compounds will not be separated. I agree 2 + 2 does equal 5
ohisay
04/12/2018
07:56
RTN Yes, I think that they might well end up doing a deal with just one company (for both compounds) as it could well be a case of 2 + 2 = 5 (if you know what I mean). It would make the IP situation a lot simpler too
timbo003
04/12/2018
07:51
I doubt they'd be split. If you were doing the deal you'd ensure it's for both rather than just one. Imo it'll simply be a deal for the lot and a question of what people are prepared to pay.
richthenewbie
03/12/2018
12:35
If the two compounds do end up with two different pharma companies, it will be interesting to see how they carve out the IP. I suspect there will be one dominant patent covering all the IP for all indications and molecules in the LOX2 program and then possibly additional patents specific to each molecule, so how would they ensure that the new owners of each molecule had complete protection and freedom to operate with their respective molecules?
timbo003
03/12/2018
12:15
All sounding very good. I kinda hope they get a surprise early bid by one of them trying to steal a march on the others.
richthenewbie
03/12/2018
10:35
I'd missed this before....from a report in October. http://www.pharmaxis.com.au/assets/Documents/pdf/02018/Other/2018-10-15-Bioshares765-PXS-extract-1.pdf There are around six potential companies that have maintained interest in Pharmaxis' LOXL2 program Pretty encouraging they have so many !
ohisay
01/12/2018
06:33
Current daily RSI here is just 15 which is historically well oversold. I nibbled a few more at 14p last week . Quite apart from the LOXL2 / SNG 001 programs there is SNG's expected "new" product collaboration which was announced at the time of the September fund raising . Finncap comment.. £0.5m to be used to fund at least one new product opportunity, similar to the earlystage work undertaken for Pharmaxis on the LOXL2 programme. Synairgen has assessed at least six potential projects over the past year, and it expects to take at least one into a research collaboration in which it will apply its technology and skill set with a view to generating early proof of concept data to determine whether to take forward into a development programme or not. All assets reviewed are novel with the potential to become best-in-class or first-in-class assets – all driven by target biology It may well be we get news of that before anything on a PXS LOXL2 farmout (though of course the toxicology results are due in December ) Finncap has end 2018 cash at £4m so you are getting a lot of bang for your buck with a current market cap of just £15m. Their 53p target price which includes nothing for any new collaborative ventures rises to 110p on a successful COPD 2a trial (results due Q2 next year) I hold a substantial position here now.
ohisay
23/11/2018
10:52
Pharmaxis.. Upbeat ProactiveInvstor Interview in Australia (23rd Nov 2018) with Gary Phillips CEO Pharmaxis.. LOXL2 are progressing positively towards a partnering deal for LOXL2 and due to complete in half year 2019. hxxps://youtu.be/4plI1IhDxNM
rosejs2
20/11/2018
03:26
http://streamz.brightcovegallery.com/pharmaxis Of the videos here I liked Jarolimek on LOXL2 (12 mins in) and Phillips on the commercialisation /business strategy (2 videos). Seems they think they have best in class products so are going to play hardball with potential licensing partners well into next year. 98m AUD market cap with 47m AUD cash is cheap too - what might SNG get (directly or indirectly) from a full PXS takeover I wonder...? There could be plenty of potential suitors after all . ie Boehringer Ingelheim (who were at the presentation) acquired the Pharmaxis phase 1 drug PXS-4728A, to initially develop it for NASH.This involved a total potential deal value of over A$750 million - they are surely not going to wait around to pay anything like that if next years results go well .
ohisay
15/11/2018
04:11
There's also an investor briefing on the 20th November.Mentioned by Arix today I note. http://streamz.brightcovegallery.com/pharmaxis ....presentations by a Boehringer Ingelheim global project manager and a research leader from the Garvan Institute of Medical Research. The event will also provide an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program currently completing phase 1 trials and extended tox studies..
ohisay
15/11/2018
03:48
Pharmaxis today..fundamentals very much underlined on LOXL2 albeit with 1/2 months delay on licensing discussions. Still very cheap with current EV just 16m$ on my calcs for both sng0001/loxl2 plus their other yet to be announced compound.. Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound ..Repeating the positive results seen in the Phase 1 trial of the first inhibitor compound announced on 10 October 2018, the excellent drug like properties demonstrated in earlier pre-clinical testing were confirmed. There were no adverse safety findings in either the first or second stages of the study and the pharmacokinetic profile showed the expected dose related increases in exposure. Significant target engagement of the LOXL2 enzyme by both compounds has now been demonstrated in blood serum for a full 24 hours from a single dose over a 14-day period, with the second compound achieving more than 85% inhibition over 24 hours from a 100mg daily dose, achieving the target for this program. Pharmaxis CEO Gary Phillips said, “Several large pharma companies are interested in the Pharmaxis program where both of our LOXL2 inhibitors have now successfully completed phase 1 studies and demonstrated a best in class profile with 24-hour inhibition of the target enzyme from a single daily dose. In a further significant scientific advancement we have also managed to underline the relevance of the program to potential partners by using our proprietary research tools to confirm that our compounds directly inhibit the activity of the raised levels of LOXL2 seen in diseased tissue from NASH and IPF animal models” Phillips continued, “The only remaining elements necessary to finalise the data package that companies are now conducting diligence on, are the 3-month toxicity studies on both compounds which are due to report later this quarter. This is slightly delayed versus initial expectations due to the availability of time slots at the contract organisations we use but successful 3-month studies will significantly enhance the LOXL2 program. Following the completion of the data package, Pharmaxis intends to conduct a final series of scientific briefings to potential partners before moving to commercial partnering discussions to secure a comprehensive licensing agreement in 2019.” https://www.proactiveinvestors.com.au/companies/news/209233/pharmaxis-receives-positive-results-from-clinical-trial-of-treatment-for-fibrotic-diseases
ohisay
30/10/2018
12:43
A deal for the Pharmaxis compound could come at any time. I am accumulating more having luckily sold some in the 20s.
nobbygnome
23/10/2018
03:18
Just thought I'd reacquaint myself with how concentrated the sharebase was after the recent placing.. https://uk.webfg.com/equity/Synairgen/director-deals Shareholdings in company .. Woodford Investment Management LLP 24,316,651 landsdowne Partners Limited 16,923,111 Richard Griffiths and controlled undertakings 15,391,112 Leonard Licht 10,700,000 IP Venture Fund LP 5,152,505 SNG Directors 3,276,403 Total 75,759,782 Shares in issue - 109,433,442 % large shareholders 69% "Free Float" - 33,673,660 shares
ohisay
23/10/2018
02:51
Yes I saw that too Timbo ..very interesting results . As I've mentioned before a 40 year old friend of ours with lifelong mild asthma was admitted to hospital a few years ago wih an exacerbation and corticosteroids was the only treatment . She died sadly two weeks later . It was one of the drivers for me being invested here in fact. Still think of how she was suffering with her breathing when we visited her in hospital.
ohisay
22/10/2018
16:04
Interesting that you should mention that ohisay, as Faron seem to think that corticosteroids could have been responsible for the disappointing result in their recent clinical using Traumakine (iv beta-interferon) to treat ARDs (see their RNS released this afternoon) https://www.investegate.co.uk/faron-pharma--oy--farn-/rns/interest-trial-update-presented-at-esicm/201810221500017971E/
timbo003
22/10/2018
06:12
Unless I'm very much mistaken thats brand new information. independent research published by Nature Communications suggests that the increased risk of pneumonia associated with the use of inhaled corticosteroids to treat exacerbations in COPD could be due to suppression of interferons and proposes that inhaled IFN-beta therapy could be protective.(1) 1. Singanayagam A, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nature Communications 2018. Doi: 10.1038/s41467-018-04574-1
ohisay
15/10/2018
07:55
Leonard Licht still accumulating here (may have been during placing). His stake up to nearly 10% now: https://uk.advfn.com/stock-market/london/synairgen-SNG/share-news/Synairgen-plc-Holdings-in-Company/78458565
richthenewbie
12/10/2018
09:40
Synairgen plc 12 October 2018 Synairgen plc ('Synairgen' or the 'Company') Result of General Meeting Further to Synairgen's announcement of 25 September 2018, the Company is pleased to announce today the passing of the Resolutions at the General Meeting held earlier today. The Placing and Subscription remain conditional on Admission of the New Ordinary Shares to AIM, which is expected to take place at 8.00 a.m. on Monday 15 September 2018. Anybody else note the mistake. Terrible really UPDATE....2nd RNS released to correct previous.
robward
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
Your Recent History
LSE
SNG
Synairgen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181215 09:26:15